Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02390622

Biotherapy for MRSA Enterocolitis

Methicillin-Resistant Staphylococcus Aureus Clinical Trial

Official title:
Fecal Microbiota Transplantation Restores Dysbiosis in Patients With Methicillin Resistant Staphylococcus Aureus Enterocolitis

Clinical Trial Summary

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major sources of nosocomial infection. Along with the widely application of antibiotics around perioperative period, MRSA infection is increasing by years.Fecal microbial transplantation (FMT),infusion of fecal preparation from a healthy donor into the GI tract of a patient is being proposed as a novel therapeutic approach to modulate diseases associated with pathological imbalances within the resident microbiota, termed dysbiosis.It has been used to treat intestinal disease such as inflammatory bowel diseases and Clostridium difficile infection, but no reports are available on its role in treating MRSA enteritis yet. vancomycin is the first choice to treat MRSA but can also lead to an increase in antibiotic resistant organisms such as vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and transfer of antibiotic resistance genes among the microbial community. So FMT seems a more harmless and reasonable measure to treat similar diseases.

Clinical Trial Description

Five cases from July, 2013 to February, 2014 were collected in Jinling hospital.They developed unexplained high fever, bloating, nausea, vomit, a high stoma output or diarrhea in the color of yellow-green with copious amounts of mucus leading to dehydration and tachycardia after short time of operation (2-4d).We got the etiology diagnosis from all the patients' gastric juice cultures which revealed MRSA.Vancocin cp had a dissatisfied effect,so FMT was supplied for treating MRSA.All the patients had a decreased intestinal flora species before FMT and the content of staphylococcus aureus almost reached half of total intestinal flora . Patients' gut bacteria after FMT gradually agree with the donors' reflected the alleviative symptoms. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02390622
Study type Interventional
Source Jinling Hospital, China
Contact Ning Li, MD
Phone 86-25-80863736
Email liningrigs@vip.sina.com
Status Recruiting
Phase N/A
Start date July 2013
Completion date February 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Completed NCT00980980 - Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) N/A
Recruiting NCT03412500 - Vancomycin Dosage Adjustment for MRSA Infections Phase 4
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Terminated NCT01196169 - Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Phase 4
Completed NCT00996112 - Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections N/A
Not yet recruiting NCT00773799 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community N/A
Not yet recruiting NCT00773864 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers N/A
Completed NCT01350479 - Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers N/A
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT01200654 - Population Pharmacokinetics of Linezolid Phase 4
Withdrawn NCT00856089 - Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization Phase 4
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02814916 - Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Phase 3
Withdrawn NCT00713674 - Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx N/A
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Not yet recruiting NCT01356472 - Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia Phase 4
Completed NCT03886623 - A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients N/A
Completed NCT01138462 - Control of MRSA in Nursing Homes: Decolonization vs Standard Precautions N/A